Refining the need for prostate biopsy and the evolving role of MRI.
Saved in:
| Title: | Refining the need for prostate biopsy and the evolving role of MRI. |
|---|---|
| Authors: | Padhani, Anwar R.1 (AUTHOR) anwar.padhani@stricklandscanner.org.uk, Woo, Sungmin2 (AUTHOR) |
| Source: | European Radiology. Jul2025, Vol. 35 Issue 7, p4013-4015. 3p. |
| Subjects: | Prostate biopsy, Magnetic resonance imaging, Group decision making, Artificial intelligence, Prostate cancer, Prostate-specific antigen, Overdiagnosis |
| Abstract: | The article discusses the evolving approach to the diagnosis and management of prostate cancer, particularly the shift towards a risk-based, imaging-driven biopsy strategy that minimizes unnecessary biopsies in men with elevated serum prostate-specific antigen (PSA) levels. The PROKOMB study provides evidence supporting the safety of deferring biopsies in men with non-suspicious MRI results, showing that only a small percentage of these men are diagnosed with clinically significant cancer after three years. The findings advocate for a personalized approach to biopsy decisions, emphasizing the importance of MRI quality and PSA density in reducing overdiagnosis and overtreatment. The article highlights the need for shared decision-making in clinical practice and suggests implications for the development of artificial intelligence software in prostate cancer detection. [Extracted from the article] |
| Copyright of European Radiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The article discusses the evolving approach to the diagnosis and management of prostate cancer, particularly the shift towards a risk-based, imaging-driven biopsy strategy that minimizes unnecessary biopsies in men with elevated serum prostate-specific antigen (PSA) levels. The PROKOMB study provides evidence supporting the safety of deferring biopsies in men with non-suspicious MRI results, showing that only a small percentage of these men are diagnosed with clinically significant cancer after three years. The findings advocate for a personalized approach to biopsy decisions, emphasizing the importance of MRI quality and PSA density in reducing overdiagnosis and overtreatment. The article highlights the need for shared decision-making in clinical practice and suggests implications for the development of artificial intelligence software in prostate cancer detection. [Extracted from the article] |
|---|---|
| ISSN: | 09387994 |
| DOI: | 10.1007/s00330-024-11322-1 |
